of a physician with written plans for monitoring the donor for side effects of accumulation of HES or cumulative effects of corticosteroids and/or G‐CSF.
Plasmapheresis donors
If plasma is donated no more than every 4 weeks (infrequent donor), the donor assessment procedures are the same as for whole blood. The FDA limitations for plasma removal are no more than 800 mL of plasma at one donation depending on the donor’s weight. These volumes may be slightly different when semiautomated instruments are used. Donors may give again in 48 hours as for platelets, but not more than twice within a 7‐day period. For donors undergoing plasmapheresis more often than once every 4 weeks (frequent donor), the serum protein must be monitored and found to be within normal limits.
Allogeneic donors for hematopoietic cell transplantation
Hematopoietic cell transplantation now uses a variety of donors, such as unrelated marrow, peripheral blood stem cells (PBSCs), or cord blood. Transfusion medicine physicians are involved in this donor selection process. The criteria for whole blood and apheresis donation serve as the basis for donor selection, but these criteria may be modified because the advantage of a particular donor may outweigh a very small or theoretical increased risk of the cellular product. Criteria intended to protect the donor are less likely to be modified, but as new donation situations, such an unrelated marrow or cord blood, have arisen, donor selection criteria for each situation were developed.
Physical examination of apheresis donors
The physical examination of cytapheresis donors is the same as for whole blood donation.
4.7 Adverse reactions in apheresis donors
General
Adverse reactions in apheresis donors (Table 4.5) are similar in character to those encountered in whole blood donation. Although double red cell collections by cytapheresis are now common, most cytapheresis procedures carried out in normal donors are plateletpheresis. Because the required interval between double red cell donation is proportionally increased, the long‐term potential for anemia/ferritin deficiency is probably similar to whole blood donation, although acute changes with each donation are greater. Normal donors undergoing plateletpheresis may report an adverse reaction following up to 50% of procedures when asked; however, such reactions cause the procedure to be discontinued only 0.1–1.0% of the time [81]. These reactions are almost entirely due to citrate toxicity and can be alleviated by slowing the rate of blood return and thus the rate of citrate infusion.
Some potential complications of apheresis apply to all types of procedures because they have to do with the instrument or activities that are common to all types of procedures, while others are unique to certain apheresis procedures [81–83].
Vasovagal reactions
Vasovagal reactions are similar to those associated with whole blood donation, but may be reduced depending on the amount of volume replacement with the method. The symptoms include weakness, pallor, diaphoresis, bradycardia, cold clammy skin, lightheadedness or fainting, and, if severe, convulsions. The treatment is as described for whole blood donors. Because the donors are usually experienced whole blood donors, they rarely experience vasovagal reactions.
Table 4.5 Potential complications and adverse reactions to cytapheresis donation.
| Reactions similar to whole blood donation |
| Citrate toxicity |
| Hematoma caused by reinfusion of red blood cells via pump |
| Mechanical hemolysis |
| Air embolus |
| Platelet depletion |
| Lymphocyte depletion |
| Plasma protein depletion |
Anticoagulation
The anticoagulant used for plateletpheresis is citrate. Cardiac toxicity caused by calcium binding can occur quickly at a very low concentration while having little impact on in vivo anticoagulation. Bleeding due to citrate anticoagulation is not a problem for donors.
Citrate toxicity
Elevations of blood citrate can cause paresthesias, muscle cramping, tetany, cardiac arrhythmia, and other symptoms. The plateletpheresis procedure involves the administration of citrate solutions to donors, resulting from the massive autologous retransfusion of 4–6 L of their blood may be withdrawn, passed through the instrument, citrated, and returned to them during the procedure. In a careful study relating the dose of citrate, symptoms, electrocardiographic changes, and ionized calcium [84] showed that when citrate infusion rates were maintained at less than 65 mg/kg/hour, donors did not experience symptoms or demonstrate electrocardiographic abnormalities. This has been confirmed in later studies [85, 86]. Donors with similar levels of hypocalcemia may demonstrate wide variability in symptoms. Using anticoagulant citrate dextrose formula A at a ratio of 1:8 with whole blood, many abnormalities were observed, including bradycardia (sometimes severe); supraventricular and ventricular premature contractions; right bundle‐branch block; ST segment elevation or depression; and tall, flattened, or inverted T waves. Some of the donors experienced nausea, vomiting, hypotension, fainting, or convulsions [87]. Even when less citrate is infused, the QT interval is almost always prolonged [88, 89]. Citrate reactions are managed by slowing the flow rate of the instrument and thus slowing the rate of citrate infusion. This is quite effective in eliminating these reactions, and most apheresis personnel are very aware of this process. Oral or intravenous calcium can also be used to reverse or prevent this condition. Citrate toxicity can also occur inadvertently if tubing is not properly placed in the pumps and the citrate solution is allowed to flow freely into the donor [90].
Circulatory effects
Because the extracorporeal volume of the cytapheresis instruments is small (usually less than 200 mL), hypovolemia is rare and these donors do not experience circulatory problems. This becomes a more significant consideration in small donors (e.g., children) or donors with very low hemoglobin levels, populations who could be undergoing therapeutic procedures.
Air embolus
Because the blood is actively pumped into the donor’s veins, there is the theoretical possibility that air could be pumped into the donor if air enters the system. Some of the early models of apheresis instruments contained bubble chambers connected to a device that stopped the pumps if the chamber became filled with air. Air emboli have occurred but without reports of serious consequences. Contemporary instruments do not contain safety devices to prevent air embolus, and so this complication remains a concern. Staff members must be aware of this possibility and ensure that containers and tubing sets do not develop leaks that would allow air to enter the system.
Hematoma
Hematomas may develop after removal of the needles used for apheresis just as after whole blood donation. There is no reason that this should be a more or less frequent complication than following whole blood donation. However, because blood is returned to the donor by active
